In the pursuit of developing novel methods for the treatment of hypoxic tumours, we designed and synthesized a series of nitroimidazoles as radio/chemosensitizing agents, targeting the tumour-associated CA IX.18 This evidence concerns the gene CA9 and neoplasm.